DRUGSFORD

Preclinical development of drugs and drug delivery technology for the treatment of inherited photoreceptor degeneration

 Coordinatore EBERHARD KARLS UNIVERSITAET TUEBINGEN 

 Organization address address: GESCHWISTER-SCHOLL-PLATZ
city: TUEBINGEN
postcode: 72074

contact info
Titolo: Dr.
Nome: Thomas
Cognome: Wheeler-Schilling
Email: send email
Telefono: +49 7071 29 87644
Fax: +49 7071 29 3774

 Nazionalità Coordinatore Germany [DE]
 Sito del progetto http://www.drugsford.eu/
 Totale costo 6˙552˙837 €
 EC contributo 4˙971˙428 €
 Programma FP7-HEALTH
Specific Programme "Cooperation": Health
 Code Call FP7-HEALTH-2012-INNOVATION-2
 Funding Scheme CP-FP
 Anno di inizio 2012
 Periodo (anno-mese-giorno) 2012-09-01   -   2015-08-31

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    EBERHARD KARLS UNIVERSITAET TUEBINGEN

 Organization address address: GESCHWISTER-SCHOLL-PLATZ
city: TUEBINGEN
postcode: 72074

contact info
Titolo: Dr.
Nome: Thomas
Cognome: Wheeler-Schilling
Email: send email
Telefono: +49 7071 29 87644
Fax: +49 7071 29 3774

DE (TUEBINGEN) coordinator 940˙660.40
2    "BIOLOG LIFE SCIENCE INSTITUTE, FORSCHUNGSLABOR UND BIOCHEMICA- VERTRIEB GMBH"

 Organization address address: Flughafendamm 9a
city: BREMEN
postcode: 28199

contact info
Titolo: Dr.
Nome: Hans-Gottfried
Cognome: Genieser
Email: send email
Telefono: +49 421 591355
Fax: +49 421 5979713

DE (BREMEN) participant 1˙290˙000.00
3    TO-BBB TECHNOLOGIES BV

 Organization address address: JH OORTWEG 19
city: LEIDEN
postcode: 2333 CH

contact info
Titolo: Dr.
Nome: Pieter
Cognome: Gaillard
Email: send email
Telefono: +31 71 33 222 51
Fax: +31 848 313 409

NL (LEIDEN) participant 1˙250˙000.00
4    LUNDS UNIVERSITET

 Organization address address: Paradisgatan 5c
city: LUND
postcode: 22100

contact info
Titolo: Dr.
Nome: Per
Cognome: Ekström
Email: send email
Telefono: +46 46 222 07 66
Fax: +46 46 222 07 74

SE (LUND) participant 750˙103.60
5    UNIVERSITA DEGLI STUDI DI MODENA E REGGIO EMILIA

 Organization address address: VIA UNIVERSITA 4
city: MODENA
postcode: 41100

contact info
Titolo: Prof.
Nome: Fabio
Cognome: Prati
Email: send email
Telefono: +39 059 2056570
Fax: +39 0592056668

IT (MODENA) participant 740˙664.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

nucleotide    treatment    drugs    constitute    smes    affecting    clinical    cyclic    cgmp    cngc    rd    bbb    pkg    groups    company    photoreceptors    photoreceptor    retinal    gc   

 Obiettivo del progetto (Objective)

'Dysregulation of cGMP is a pathological hallmark of inherited retinal degenerations (RD) affecting photoreceptors, the sensory cells of the retina. These RDs, including Retinitis Pigmentosa, Lebers Congenital Amaurosis, and Achromatopsia, are major causes of blindness, affecting approximately one in every 2000 individuals worldwide, and remain without effective treatment. In photoreceptors, cGMP is produced by retinal guanylyl cyclase (GC). The two main cGMP targets are cyclic nucleotide gated ion channels (CNGC) and cGMP-dependent protein kinase (PKG). Since attenuation of PKG and CNGC activity can reduce photoreceptor cell death, both proteins constitute potential targets to prevent RD. Recent data suggest that blocking retinal GC may also constitute a viable therapeutic approach. This consortium will study and develop targeted compounds and delivery systems aimed at preventing photoreceptor damage in preclinical disease models. Towards this goal, two SMEs have teamed up with three academic research groups focused on retinal degeneration: the German company BIOLOG specializes on development of cyclic nucleotide based drugs targeting PKG, CNGC, and GC; the Dutch company to-BBB develops systems to deliver drugs across the blood brain/retinal barrier (BBB, BRB, resp.); the groups of V. Marigo (Modena, Italy), P. Ekström (Lund, Sweden), and F. Paquet-Durand (Tübingen, Germany) have a strong and joint collaborative track record of studying photoreceptor degenerative mechanisms as well as on testing and evaluating drug treatment effects. Manufacturing of the most promising drugs fitted to a suitable delivery system will be scaled up towards clinical-size batches and studied towards efficacy, toxicology and off-target effects in model animals. The results of the project will allow the SMEs to further co-develop these drugs towards translation into clinical studies, addressing the high needs of RD patients and the high economic benefit of such therapies.'

Altri progetti dello stesso programma (FP7-HEALTH)

PARCIVAL (2012)

Partner Network for a Clinically Validated Multi-Analyte Lab-on-a-Chip Platform

Read More  

ESMART (2014)

Randomised controlled trial to evaluate electronic Symptom Management using the Advanced Symptom Management System (ASyMS) Remote Technology for patients with cancers

Read More  

EURONEUT-41 (2008)

EUROpean consortium on NEUTralising antibodies using gp41

Read More